



TRADGENE Laboratory
Translational Control and Gene Therapy of Vascular Diseases

Object : Revised Manuscript No 14666

Toulouse, November 24, 2014

Dear Editor,

Please find enclosed the edited manuscript in word format ESPS Ms No14666 WJEM-Review.doc

Title: IRES-based vectors for combined gene therapy

Authors: Edith Renaud-Gabardos, Fransky Hantelys, Florent Morfoisse, Xavier Chaufour, Barbara Garmy-Susini and Anne-Catherine Prats.

Name of journal: World Journal of Experimental Medicine

ESPS Manuscript No 14666.

The comments of the reviewers (only reviewer 2 asked for modifications) have been taken into account. The modifications in the text have been indicated in red.

Answer to reviewer 2 comments :

1) Figure 1B line 2: The presence of IRES transacting factors could be symbolized

-> Done

2) Page 9 line 8: CD70 and CD154 or CD80 is mentioned. Add also CD70+CD154 in Table 2 line fibrosarcoma.

-> The only co-expression published is CD70 + CD80. CD154 has been co-expressed using an IRES-based vector but only with a resistance gene. It has been removed from the text.

3) Page 3 line 30: In "These observations incited us to deepen the features..." incited could be changed for prompted or invited

-> Done

4) Page 5: the abbreviation EMCV should be defined

-> Done

TRADGENE EA4554
Contrôle de la traduction et thérapie génique des
pathologies vasculaires
Institut des Maladies Métaboliques et Cardiovasculaires
Université Paul Sabatier
1 avenue Jean Poulhès
BP 84225
31432 Toulouse Cedex 4 - France
Tél. 33 (0)5 31 22 40 87 Fax. 33 (0)5 61 32 56 22
E-mail : Anne-Catherine.Prats@inserm.fr

5) Page 6 line 9: “are useful to control transgene” should be preferred to “are useful to obtain a controlled transgene”

-> Done

6) Page 8 line 23: PDGF. To be homogeneous with Table 1 change for PDGFB

-> Done

7) I suggest reducing the number of references.

We have analysed carefully the references to identify useless ones but did not find any. The references have been chosen carefully to try to be exhaustive and cite original papers rather than reviews. All of them are cited to support the argumentation of the text.

Thank you again for publishing our manuscript in World Journal of Experimental Medicine.

Best regards,



Anne-Catherine Prats, PhD

Research Director in Inserm

TRADGENE EA4554
Contrôle de la traduction et thérapie génique des
pathologies vasculaires
Institut des Maladies Métaboliques et Cardiovasculaires
Université Paul Sabatier
1 avenue Jean Poulhès
BP 84225
31432 Toulouse Cedex 4 - France
Tél. 33 (0)5 31 22 40 87 Fax. 33 (0)5 61 32 56 22
E-mail : Anne-Catherine.Prats@inserm.fr